Danielle Park


Danielle obtained her PhD in 2012 at the University of NSW, Sydney, where she was involved in the preclinical development of a cell death imaging agent, used to assess chemotherapy efficacy. She later moved to London to the laboratory of Dr Erik Sahai as a Post-Doctoral Fellow to explore how stromal fibroblasts create ‘superhighways’ for cancer invasion and metastasis. In 2019, Danielle took on an Industry bridging position in the laboratory of Dr Caroline Hill in collaboration with Oncology R&D AstraZeneca where she currently leads the preclinical validation of novel therapy for breast and pancreatic cancer.

Displaying 1 - 7 of 7
Last updated : 02 March 2024 02:56